Search
Ruserontinib
go.drugbank.com/drugs/DB21555InvestigationalRuserontinib is under investigation in clinical trial NCT04716114 (A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated). … The usage of the INN stem '-tinib' in the name indicates that Ruserontinib is a tyrosine kinase inhibitor.
Enbezotinib
go.drugbank.com/drugs/DB21565InvestigationalEnbezotinib is under investigation in clinical trial NCT04161391 (Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations). … The usage of the INN stem '-tinib' in the name indicates that Enbezotinib is a tyrosine kinase inhibitor.
Tengonermin
go.drugbank.com/drugs/DB16689Investigational[A233270] A study also demonstrated that binding of the NGR-motif to CD13 determined both the homing of NGR-hTNF to tumor vessels and the increase in its antiangiogenic activity.[A233270]
Chlorophetanol
go.drugbank.com/drugs/DB11368ExperimentalChlorophetanol is an agent known to have antifungal activities.
Ferric oxyhydroxide
go.drugbank.com/drugs/DB14695ExperimentalAn antiferromagnetic material; constitutes the core of natural ferritin.
IK-930
go.drugbank.com/drugs/DB18149InvestigationalIK-930 is an oral, paralog-selective TEAD inhibitor.
RO-5028442
go.drugbank.com/drugs/DB12721InvestigationalRO5028442 has been used in trials studying Autistic Disorder.
ACT-451840
go.drugbank.com/drugs/DB13054InvestigationalACT-451840 has been used in trials studying Malaria.
Plamotamab
go.drugbank.com/drugs/DB18944InvestigationalPlamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (
161Tb-PSMA-1
go.drugbank.com/drugs/DB33964Experimental161Tb-PSMA-1 is a small molecule drug. 161Tb-PSMA-1 is under investigation in clinical trial NCT07828249 (Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal